HUTCHMED (China) HCM
NASDAQ HCM
$12.52 -0.07 (-0.60%)
At close: Aug 20, 2026 · 12:55 PM UTC

HUTCHMED (China) (HCM) Net Income towards Common Stockholders (2014 - 2021)

HUTCHMED (China) (HCM) posted quarterly Net Income towards Common Stockholders of $61.0 million for Q2 2021, up 165.04% year-over-year from $23.0 million in Q2 2020, and up 47.65% quarter-over-quarter from $41.3 million in Q1 2021.

HUTCHMED (China) (HCM) Net Income towards Common Stockholders (2014 - 2021) Analysis & Trends

HUTCHMED (China) (HCM) has reported Net Income towards Common Stockholders for 8 consecutive years, with $61.0 million the latest figure, recorded in Q2 2021.

  • In Q2 2021, Net Income towards Common Stockholders rose 165.04% year-over-year to $61.0 million; the TTM figure through Dec 2022 stood at $61.0 million (down 40.38% YoY), while the FY2025 annual figure was $64.4 million, up 1226.74% from the prior year.
  • Net Income towards Common Stockholders climbed to $61.0 million in Q2 2021 per HCM's latest filing, from $41.3 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $70.1 million in Q2 2018 and bottomed at -$99.4 million in Q2 2019.
  • Historically, Net Income towards Common Stockholders has averaged $7.4 million across 5 years, with a median of $21.7 million in 2018.
  • Annual changes were most pronounced in 2018 — Net Income towards Common Stockholders soared 74758.62% — and 2019, when it plunged 367.87%.
  • HUTCHMED (China)'s Net Income towards Common Stockholders stood at $29000.0 in 2017, then jumped by 74758.62% to $21.7 million in 2018, then sank by 276.22% to -$38.3 million in 2019, then jumped by 160.21% to $23.0 million in 2020, then soared by 165.04% to $61.0 million in 2021.
  • Business Quant data shows HCM's Net Income towards Common Stockholders at $61.0 million in Q2 2021, $41.3 million in Q1 2021, and $23.0 million in Q2 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 43.96 Bn 43.00 Bn - -
2 Teva Pharmaceutical Industries 43.23 Bn 39.58 Bn 2.15 Bn -576.00 Mn
3 Zoetis 31.76 Bn 30.08 Bn 1.05 Bn 866.00 Mn
4 Takeda Pharmaceutical 28.68 Bn 22.88 Bn 5.10 Bn 710.19 Mn
5 United Therapeutics 22.27 Bn 19.61 Bn 683.80 Mn 333.00 Mn
6 Viatris 18.69 Bn 17.81 Bn 1.46 Bn -118.80 Mn
7 Neurocrine Biosciences 15.56 Bn 15.17 Bn 935.80 Mn 144.40 Mn
8 Elanco Animal Health 11.78 Bn 11.25 Bn 798.00 Mn 54.00 Mn
9 Dr Reddys Laboratories 10.13 Bn 9.97 Bn - -
10 HUTCHMED (China) 2.17 Bn 2.17 Bn - 1.26 Bn

Historic Data

Download Data
DateValue
Jun 30, 2021 61.05 Mn
Mar 31, 2021 41.35 Mn
Jun 30, 2020 23.03 Mn
Mar 31, 2020 26.66 Mn
Dec 31, 2019 -38.26 Mn
Sep 30, 2019 -34.24 Mn
Jun 30, 2019 -99.44 Mn
Mar 31, 2019 33.60 Mn
Dec 31, 2018 21.71 Mn
Sep 30, 2018 12.78 Mn
Jun 30, 2018 70.12 Mn
Mar 31, 2018 -22.31 Mn
Dec 31, 2017 29,000.00
Dec 31, 2016 -248,000.00
Jun 30, 2016 29.59 Mn
Dec 31, 2015 -160,000.00
Jun 30, 2015 23.42 Mn
Dec 31, 2014 -3.06 Mn